M Holdings Securities Inc. purchased a new stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX – Get Rating) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 10,650 shares of the company’s stock, valued at approximately $148,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in MGTX. Adage Capital Partners GP L.L.C. boosted its position in MeiraGTx by 34.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,863,054 shares of the company’s stock worth $67,969,000 after buying an additional 738,054 shares during the period. 683 Capital Management LLC boosted its position in MeiraGTx by 3.0% during the 4th quarter. 683 Capital Management LLC now owns 1,355,000 shares of the company’s stock worth $32,168,000 after buying an additional 39,900 shares during the period. State Street Corp boosted its position in MeiraGTx by 6.0% during the 1st quarter. State Street Corp now owns 538,323 shares of the company’s stock worth $7,456,000 after buying an additional 30,381 shares during the period. Rhenman & Partners Asset Management AB boosted its position in MeiraGTx by 11.1% during the 1st quarter. Rhenman & Partners Asset Management AB now owns 500,000 shares of the company’s stock worth $6,925,000 after buying an additional 50,000 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in MeiraGTx by 34.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 401,385 shares of the company’s stock worth $5,559,000 after buying an additional 103,686 shares during the period. 62.85% of the stock is owned by institutional investors.
MeiraGTx Stock Down 3.6 %
Shares of NASDAQ MGTX opened at $8.69 on Tuesday. The company has a market capitalization of $388.54 million, a P/E ratio of -3.83 and a beta of 1.73. MeiraGTx Holdings plc has a 52-week low of $6.59 and a 52-week high of $24.89. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.55 and a current ratio of 1.55. The company’s 50 day moving average price is $9.02 and its 200-day moving average price is $10.03.
Wall Street Analyst Weigh In
MeiraGTx Company Profile
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases.
- Get a free copy of the StockNews.com research report on MeiraGTx (MGTX)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.